EMA CONSIDERS CHANGING EU CONTROLS ON WEIGHT PILLS

BY KEITH NUTHALL THE EUROPEAN Medicines Agency (EMA) is consulting on potential changes to its guidance on the development and use of weight control medicines, because of concerns risks to patients are being underestimated. It has released a consultation paper noting "given the dramatic worldwide increase of obesity and overweight, in depth evaluation of overall benefit/risk is a crucial issue." One particular concern is current EU market approval guidelines include no requirement to demonstrate impacts on cardiovascular problems: ...


Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.